Bispecific Antibodies in Multiple Myeloma: Opportunities to Enhance Efficacy and Improve Safety.
Issue Date
2023-03-17Keywords
T-cell engagersbispecific antibodies
myeloma
Tumour microenvironment
Metadata
Show full item recordJournal
CancersDOI
10.3390/cancers15061819PubMed ID
36980705Item Type
ArticleOther
Language
enISSN
2072-6694ae974a485f413a2113503eed53cd6c53
10.3390/cancers15061819
Scopus Count
Collections
The following license files are associated with this item:
- Creative Commons
Related articles
- Recent advances and future perspectives of T-cell engagers in lymphoid malignancies.
- Authors: Shirouchi Y, Maruyama D
- Issue date: 2024 Apr 6
- The evolving status of immunotherapies in multiple myeloma: the future role of bispecific antibodies.
- Authors: Swan D, Routledge D, Harrison S
- Issue date: 2022 Feb
- Bispecific Antibodies for the Management of Relapsed/Refractory Multiple Myeloma.
- Authors: Tacchetti P, Barbato S, Mancuso K, Zamagni E, Cavo M
- Issue date: 2024 Jun 26
- Bispecific Antibodies for Multiple Myeloma: Recent Advancements and Strategies for Increasing Their Efficacy.
- Authors: Wang M, Wang C, Deng J, Wang H, Sun C, Luo S, Hu Y
- Issue date: 2024 Jun 17
- Current State of the Art and Prospects of T Cell-Redirecting Bispecific Antibodies in Multiple Myeloma.
- Authors: Hosny M, Verkleij CPM, van der Schans J, Frerichs KA, Mutis T, Zweegman S, van de Donk NWCJ
- Issue date: 2021 Oct 6